Impact of four times daily dosing of oral treprostinil on tolerability and daily dose achieved in pulmonary hypertension

PVRI Member Authors: Marc Simon

Abstract

Oral treprostinil (TRE) is a prostacylin that is approved for the treatment of patients with pulmonary arterial hypertension (PAH). Dosing is approved for two or three times daily (t.i.d.); however, adverse effects, including gastrointestinal-related symptoms, may limit the ability to reach optimal doses. We report our experience with a four times daily (q.i.d.) regimen of oral TRE for goal-directed therapy of PAH. We describe three patients that were transitioned from infusion or inhaled TRE to oral TRE with initial t.i.d. dosing over a four-day hospital stay. All patients were subsequently further dose-adjusted in the outpatient setting; however, adverse effects limited additional up-titration despite persistent dyspnea. In a carefully monitored outpatient setting, patients were switched from t.i.d. to q.i.d. dosing of oral TRE. All three patients were successfully dosed q.i.d., having achieved a higher total daily dose compared with a t.i.d. dose regimen. Furthermore, patients were able to maintain functional class II symptoms with mitigation of adverse effects using the q.i.d. dose regimen.

Read the full article online

Topics

Pharmacology: Pharmacokinetics and Pharmacodynamics
Pulmonary Arterial Hypertension
Pulmonary Hypertension

Authors

James C. Coons, Cheryl Bunner, David C. Ishizawar, Michael G. Risbano, Belinda Rivera-Lebron, Michael A. Mathier, Stephen Y. Chan

Published in:

Pulmonary Circulation Vol 8: No 1 cover image

March 2018

Pulmonary Circulation Vol 8: No 1

View this journal

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI
standard-example-image.jpg